Trega Biosciences Announces New Board Member
SAN DIEGO, March 22 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA) today announced the addition of Bruce L.A. Carter, Ph.D. to its Board of Directors. Dr. Carter fills a vacant position on the Board as a Class II director with a term expiring in 2002.
Dr. Carter currently serves as Corporate Executive Vice President and Chief Scientific Officer at Novo Nordisk located in Denmark where he is responsible for their global research strategy and external healthcare collaborations. In addition, he is President of ZymoGenetics, Inc. Previously, he was Head of Molecular Genetics at G.D. Searle & Co., Ltd. Dr. Carter serves as director on the Boards of ZymoGenetics, AVI BioPharma and Skeletech.
"I am delighted that Bruce has joined our Board," said Michael G. Grey, president and chief executive officer. "He brings to Trega expertise from his experience in both the pharmaceutical and biotechnology arenas. He is a business leader as well as a respected scientist and Trega should benefit greatly from his contribution."
Trega Biosciences is an information-driven company focused on accelerating drug discovery from disease targets to clinical candidates through its iDiscovery(TM) technologies. These technologies, comprised of information- rich small molecule combinatorial chemistry and in vitro assays coupled with predictive models and proprietary databases, are designed to rapidly create novel drug candidates having greater chances of clinical success. Trega's iDiscovery(TM) technologies span the drug discovery process, beginning with the creation of novel compounds to the delivery of uniquely qualified drug leads to the pharmaceutical and life science industries.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including whether the reported transition within the Board will occur without disrupting Trega's business and operations, whether any proposed product can be successfully formulated, scaled-up, developed, and commercialized, whether regulatory approvals can be obtained, the impact of competitive products and pricing, the financial condition of Trega in the future, whether any collaborations or alliances will be successful, and other risks detailed from time to time in Trega's Securities and Exchange Commission filings. These forward-looking statements represent Trega's judgment as of the date of this release. Actual results may differ materially from those projected. Trega disclaims, however, any intent or obligation to update these forward-looking statements.
Trega's releases are on the World Wide Web at trega.com and PR Newswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
CO: Trega Biosciences, Inc.
ST: California
IN: MTC BIO
SU: PER
03/22/2000 08:00 EST prnewswire.com |
